Skye Bioscience Inc. has highlighted new data on its investigational obesity treatment, nimacimab, in a recent corporate presentation. According to the company, nimacimab is designed to complement existing GLP-1 therapies, providing approximately 3% additional weight loss over semaglutide alone at 26 weeks, with continued benefit over time. The presentation notes that nimacimab may offer more durable weight loss, with a lower post-treatment rebound rate and a favorable body-composition profile compared to GLP-1 monotherapy. The combination of nimacimab with incretin therapies was reported to show no increase in gastrointestinal side effects or neuropsychiatric adverse events. Skye Bioscience positions nimacimab as a differentiated, combination-friendly option with a peripheral CB1 mechanism, targeting both GLP-1 non-responders and those seeking enhanced weight loss outcomes. The company also reported a clear pharmacokinetic and exposure-response understanding from Phase 2a trials, supporting further clinical development. You can access the full presentation through the link below.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.
Comments